PMID- 24431106
OWN - NLM
STAT- MEDLINE
DCOM- 20141006
LR  - 20191210
IS  - 1552-4604 (Electronic)
IS  - 0091-2700 (Linking)
VI  - 54
IP  - 3
DP  - 2014 Mar
TI  - How MDMA's pharmacology and pharmacokinetics drive desired effects and harms.
PG  - 245-52
LID - 10.1002/jcph.266 [doi]
AB  - 3,4-Methylenedioxymethamphetamine (MDMA) is an agent of abuse that has been used 
      by over 16 million Americans. Increased energy, elevated mood, bonding with 
      others, and psychedelic effects are desired effects while liver damage, extended 
      depressed mood, sexual assault, rhabdomyolysis, serotonin syndrome, multiorgan 
      failure, cardiovascular events, arrhythmias, and death are possible adverse 
      effects. These desirable and adverse effects of MDMA are extensions of its 
      fascinating pharmacologic and pharmacokinetic profile. In addition to 
      methamphatemine like effects, MDMA also has mescaline like effects and increases 
      the release of cortisol, oxytocin, and antidiuretic hormone. The desirable 
      effects of MDMA are accentuated by the rave or electronic dance music scene where 
      warm temperatures, vigorous dancing, loud music, and light shows accentuate some 
      of the responses. However, the same environment increases the risk of certain 
      harms. Knowledge of the constellation of these factors is needed for education, 
      prevention of harm, and treatment.
CI  - (c) 2014, The American College of Clinical Pharmacology.
FAU - Michael White, C
AU  - Michael White C
AD  - University of Connecticut and Hartford Hospital, Hartford, CT, USA.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20140122
PL  - England
TA  - J Clin Pharmacol
JT  - Journal of clinical pharmacology
JID - 0366372
RN  - 0 (Hallucinogens)
RN  - 0 (Illicit Drugs)
RN  - 0 (Serotonin Agents)
RN  - KE1SEN21RM (N-Methyl-3,4-methylenedioxyamphetamine)
SB  - IM
MH  - Drug Interactions
MH  - Europe/epidemiology
MH  - Hallucinogens/adverse effects/pharmacokinetics/*pharmacology
MH  - Humans
MH  - Illicit Drugs/adverse effects/pharmacokinetics/*pharmacology
MH  - N-Methyl-3,4-methylenedioxyamphetamine/adverse 
      effects/pharmacokinetics/*pharmacology
MH  - Prevalence
MH  - Serotonin Agents/adverse effects/pharmacokinetics/*pharmacology
MH  - Substance-Related Disorders/epidemiology
MH  - United States/epidemiology
OTO - NOTNLM
OT  - MDMA
OT  - ecstasy
OT  - hyperpyrexia
OT  - hyponatremia
OT  - molly
OT  - rhabdomyolysis
EDAT- 2014/01/17 06:00
MHDA- 2014/10/07 06:00
CRDT- 2014/01/17 06:00
PHST- 2013/12/05 00:00 [received]
PHST- 2014/01/08 00:00 [accepted]
PHST- 2014/01/17 06:00 [entrez]
PHST- 2014/01/17 06:00 [pubmed]
PHST- 2014/10/07 06:00 [medline]
AID - 10.1002/jcph.266 [doi]
PST - ppublish
SO  - J Clin Pharmacol. 2014 Mar;54(3):245-52. doi: 10.1002/jcph.266. Epub 2014 Jan 22.